Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 24

1.

Olaratumab Exerts Antitumor Activity in Preclinical Models of Pediatric Bone and Soft Tissue Tumors through Inhibition of Platelet-Derived Growth Factor Receptor α.

Lowery CD, Blosser W, Dowless M, Knoche S, Stephens J, Li H, Surguladze D, Loizos N, Luffer-Atlas D, Oakley GJ 3rd, Guo Q, Iyer S, Rubin BP, Stancato L.

Clin Cancer Res. 2018 Feb 15;24(4):847-857. doi: 10.1158/1078-0432.CCR-17-1258. Epub 2017 Nov 30.

2.

Platelet-Derived Growth Factor Receptor α Contributes to Human Hepatic Stellate Cell Proliferation and Migration.

Kikuchi A, Pradhan-Sundd T, Singh S, Nagarajan S, Loizos N, Monga SP.

Am J Pathol. 2017 Oct;187(10):2273-2287. doi: 10.1016/j.ajpath.2017.06.009. Epub 2017 Jul 20.

3.

Phase 1 study of narnatumab, an anti-RON receptor monoclonal antibody, in patients with advanced solid tumors.

LoRusso PM, Gounder M, Jalal SI, André V, Kambhampati SRP, Loizos N, Hall J, Holzer TR, Nasir A, Cosaert J, Kauh J, Chiorean EG.

Invest New Drugs. 2017 Aug;35(4):442-450. doi: 10.1007/s10637-016-0413-0. Epub 2017 Feb 4.

4.

Inhibition of fibroblast growth factor receptor 3-dependent lung adenocarcinoma with a human monoclonal antibody.

Yin Y, Ren X, Smith C, Guo Q, Malabunga M, Guernah I, Zhang Y, Shen J, Sun H, Chehab N, Loizos N, Ludwig DL, Ornitz DM.

Dis Model Mech. 2016 May 1;9(5):563-71. doi: 10.1242/dmm.024760. Epub 2016 Apr 7.

5.

A human monoclonal antibody targeting the stem cell factor receptor (c-Kit) blocks tumor cell signaling and inhibits tumor growth.

Lebron MB, Brennan L, Damoci CB, Prewett MC, O'Mahony M, Duignan IJ, Credille KM, DeLigio JT, Starodubtseva M, Amatulli M, Zhang Y, Schwartz KD, Burtrum D, Balderes P, Persaud K, Surguladze D, Loizos N, Paz K, Kotanides H.

Cancer Biol Ther. 2014 Sep;15(9):1208-18. doi: 10.4161/cbt.29523. Epub 2014 Jun 12.

6.

A phase I study of olaratumab, an anti-platelet-derived growth factor receptor alpha (PDGFRα) monoclonal antibody, in patients with advanced solid tumors.

Chiorean EG, Sweeney C, Youssoufian H, Qin A, Dontabhaktuni A, Loizos N, Nippgen J, Amato R.

Cancer Chemother Pharmacol. 2014 Mar;73(3):595-604. doi: 10.1007/s00280-014-2389-9. Epub 2014 Jan 23.

PMID:
24452395
7.

Platelet-derived growth factor receptor alpha (PDGFRα) targeting and relevant biomarkers in ovarian carcinoma.

Matsuo K, Nishimura M, Komurov K, Shahzad MM, Ali-Fehmi R, Roh JW, Lu C, Cody DD, Ram PT, Loizos N, Coleman RL, Sood AK.

Gynecol Oncol. 2014 Jan;132(1):166-75. doi: 10.1016/j.ygyno.2013.10.027. Epub 2013 Oct 29.

8.

Stromal platelet-derived growth factor receptor α (PDGFRα) provides a therapeutic target independent of tumor cell PDGFRα expression in lung cancer xenografts.

Gerber DE, Gupta P, Dellinger MT, Toombs JE, Peyton M, Duignan I, Malaby J, Bailey T, Burns C, Brekken RA, Loizos N.

Mol Cancer Ther. 2012 Nov;11(11):2473-82. doi: 10.1158/1535-7163.MCT-12-0431. Epub 2012 Aug 28.

9.

Rationale for the development of IMC-3G3, a fully human immunoglobulin G subclass 1 monoclonal antibody targeting the platelet-derived growth factor receptor alpha.

Shah GD, Loizos N, Youssoufian H, Schwartz JD, Rowinsky EK.

Cancer. 2010 Feb 15;116(4 Suppl):1018-26. doi: 10.1002/cncr.24788.

10.

Development of a fully human anti-PDGFRbeta antibody that suppresses growth of human tumor xenografts and enhances antitumor activity of an anti-VEGFR2 antibody.

Shen J, Vil MD, Prewett M, Damoci C, Zhang H, Li H, Jimenez X, Deevi DS, Iacolina M, Kayas A, Bassi R, Persaud K, Rohoza-Asandi A, Balderes P, Loizos N, Ludwig DL, Tonra J, Witte L, Zhu Z.

Neoplasia. 2009 Jun;11(6):594-604.

11.

Lack of detection of agonist activity by antibodies to platelet-derived growth factor receptor alpha in a subset of normal and systemic sclerosis patient sera.

Loizos N, Lariccia L, Weiner J, Griffith H, Boin F, Hummers L, Wigley F, Kussie P.

Arthritis Rheum. 2009 Apr;60(4):1145-51. doi: 10.1002/art.24365.

12.

Identifying protein interactions by hydroxyl-radical protein footprinting.

Loizos N.

Curr Protoc Protein Sci. 2004 Nov;Chapter 19:Unit 19.9. doi: 10.1002/0471140864.ps1909s38.

PMID:
18429254
13.

Platelet-derived growth factor receptor-alpha: a novel therapeutic target in human hepatocellular cancer.

Stock P, Monga D, Tan X, Micsenyi A, Loizos N, Monga SP.

Mol Cancer Ther. 2007 Jul;6(7):1932-41. Epub 2007 Jun 29.

14.

An antibody directed against PDGF receptor beta enhances the antitumor and the anti-angiogenic activities of an anti-VEGF receptor 2 antibody.

Shen J, Vil MD, Zhang H, Tonra JR, Rong LL, Damoci C, Prewett M, Deevi DS, Kearney J, Surguladze D, Jimenez X, Iacolina M, Bassi R, Zhou K, Balderes P, Mangalampalli VR, Loizos N, Ludwig DL, Zhu Z.

Biochem Biophys Res Commun. 2007 Jun 15;357(4):1142-7. Epub 2007 Apr 19.

PMID:
17462601
15.
16.

Targeting the platelet-derived growth factor receptor alpha with a neutralizing human monoclonal antibody inhibits the growth of tumor xenografts: implications as a potential therapeutic target.

Loizos N, Xu Y, Huber J, Liu M, Lu D, Finnerty B, Rolser R, Malikzay A, Persaud A, Corcoran E, Deevi DS, Balderes P, Bassi R, Jimenez X, Joynes CJ, Mangalampalli VR, Steiner P, Tonra JR, Wu Y, Pereira DS, Zhu Z, Ludwig DL, Hicklin DJ, Bohlen P, Witte L, Kussie P.

Mol Cancer Ther. 2005 Mar;4(3):369-79.

17.

Mapping protein-ligand interactions by hydroxyl-radical protein footprinting.

Loizos N.

Methods Mol Biol. 2004;261:199-210. Review.

PMID:
15064460
18.
19.

Mapping protein-ligand interactions by footprinting, a radical idea.

Loizos N, Darst SA.

Structure. 1998 Jun 15;6(6):691-5. Review. No abstract available.

20.

Determinants for Escherichia coli RNA polymerase assembly within the beta subunit.

Wang Y, Severinov K, Loizos N, Fenyö D, Heyduk E, Heyduk T, Chait BT, Darst SA.

J Mol Biol. 1997 Aug 1;270(5):648-62.

PMID:
9245594
21.
22.

Evolution of mobile group I introns: recognition of intron sequences by an intron-encoded endonuclease.

Loizos N, Tillier ER, Belfort M.

Proc Natl Acad Sci U S A. 1994 Dec 6;91(25):11983-7.

23.

The td intron endonuclease I-TevI makes extensive sequence-tolerant contacts across the minor groove of its DNA target.

Bryk M, Quirk SM, Mueller JE, Loizos N, Lawrence C, Belfort M.

EMBO J. 1993 Oct;12(10):4040-1. No abstract available.

24.

The td intron endonuclease I-TevI makes extensive sequence-tolerant contacts across the minor groove of its DNA target.

Bryk M, Quirk SM, Mueller JE, Loizos N, Lawrence C, Belfort M.

EMBO J. 1993 May;12(5):2141-9. Erratum in: EMBO J. 1993 Oct;12(10):4040-1.

Supplemental Content

Loading ...
Support Center